-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bemdaneprocel in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Bemdaneprocel in Parkinson's DiseaseDrug Details:DA-01 is under development for the treatment of Parkinson's disease. The therapeutic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REGN-5381 in Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5381 in Hypertension Drug Details: REGN5381 is under development for the treatment of hypertension. It...
-
Company Profile
![]()
Editas Medicine Inc – Company Profile
Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company works in collaboration with Allergan/ AbbVie Inc, AskBio, BlueRock Therapeutics,...
Add to Basket -
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – DA-01
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry DA-01 Drug Details DA-01 is under development for the treatment of Parkinson's disease. The...
-
Product Insights
![]()
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
![]()
Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness, and weight loss. Treatment includes immunosuppressants. The GVHD pipeline market research report provides comprehensive information on the therapeutics under development for GVHD, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
![]()
Myocardial Infarction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Myocardial infarction pipeline market research report provides a comprehensive overview on the therapeutics under development for Myocardial infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial infarction and features...
-
Product Insights
![]()
Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bone Marrow Transplant Rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. The Bone Marrow Transplant Rejection - drugs in development research report provides a comprehensive overview on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis...
-
Product Insights
![]()
Congestive Heart Failure (Heart Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Congestive heart failure (heart failure) report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure...
-
Product Insights
New![]()
Kareevlei Project
The Kareevlei Project is a diamond mine in South Africa. It is currently in operation. Empower your strategies with our Kareevlei Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital...
-
Company Insights
![]()
Bayer AG – Enterprise Tech Ecosystem Series
Bayer implemented a five-year global IT strategy to drive its digital business transformation by aligning itself to new technologies like cloud, IoT, and AI among others, and using them to create various digital platforms. Bayer is digitally transforming its internal operations to improve productivity and efficiency and have cost-effective functional areas. For example, it deployed a digital twin-based scheduling program at its pharma manufacturing site in Italy, bringing improvements in its quality-control lab, and transforming it into a smart factory....
-
Track & Monitor
![]()
Pharmaceuticals Industry Deals and Trends in August 2019 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for August 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2019. The report portrays detailed comparative data on the number of deals and their value in the last...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.